Lipi EZ 20 Tablet is a combination lipid-lowering medication containing Atorvastatin 20 mg and Ezetimibe 10 mg, indicated for the management of hypercholesterolemia and mixed dyslipidemia. Atorvastatin, a statin class drug, functions by inhibiting HMG-CoA reductase, the key enzyme in cholesterol biosynthesis, thereby reducing low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C). Ezetimibe acts by selectively inhibiting the intestinal absorption of cholesterol and related phytosterols, leading to decreased delivery of intestinal cholesterol to the liver. The combination therapy offers a complementary mechanism of action, resulting in enhanced LDL-C reduction compared to monotherapy with either agent alone. Lipi EZ 20 is prescribed for patients who require additional lipid lowering beyond diet and lifestyle modifications, particularly those with primary hypercholesterolemia, homozygous familial hypercholesterolemia, or mixed dyslipidemia. It may also be used in patients intolerant to higher doses of statins or those who do not achieve target lipid levels with statin monotherapy. The medication should be administered under medical supervision, with periodic monitoring of lipid profiles, liver function tests, and creatine kinase levels to detect potential adverse effects such as myopathy or hepatotoxicity.